Company news
Gt Biopharma, Inc. (NASDAQ:GTBP) news
Gt Biopharma, Inc. news releases on 6ix. Latest, Aug 11, 2022: GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update
Press releases — page 2
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update
August 10, 2022
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress
June 9, 2022
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update
May 15, 2022
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022
April 10, 2022
GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
March 27, 2022
GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting
March 20, 2022
GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences
February 23, 2022
GT Biopharma Appoints Manu Ohri as Chief Financial Officer
February 17, 2022
GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 5, 2022
GT BioPharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 9, 2021
GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey
November 7, 2021
GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021
September 14, 2021
GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies
September 12, 2021
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies
September 8, 2021
GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer
August 22, 2021
GT Biopharma Provides Second Quarter 2021 Business Update
August 12, 2021
GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results
August 5, 2021
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
August 2, 2021
GT Biopharma Announces $16 million in Warrant Exercise Proceeds
July 27, 2021
GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota
July 6, 2021
GT Biopharma Announces Interim GTB-3550 Trike™ Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference
June 22, 2021
GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET
May 17, 2021
GT Biopharma Reports First Quarter 2021 Results
May 16, 2021
GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates
May 11, 2021
GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical Officer and Jeffrey S. Miller, M.D. to Consulting Chief Scientific Officer
April 25, 2021
GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update
April 18, 2021
GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients
April 11, 2021
GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial
April 7, 2021
GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results
March 16, 2021
GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer
March 7, 2021
GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment
March 3, 2021
GT Biopharma Transfers TriKE™ Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple Liquid And Solid Tumor Clinical Trials
February 17, 2021
GT Biopharma Announces Closing of $23.7 Million Public Offering
February 15, 2021
GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market
February 10, 2021
GT Biopharma Appoints Two New Independent Directors
January 18, 2021
GT Biopharma Announces Eighth Patient Begins Treatment Of GTB-3550
January 11, 2021
GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call
January 3, 2021
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
December 27, 2020
GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENT
December 20, 2020
GT Biopharma And Cytovance Biologics Announce Milestone Achievement
December 16, 2020
GT Biopharma Submits Application for Uplisting to the NASDAQ Capital Market
December 13, 2020
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients
December 7, 2020
GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of Directors
November 18, 2020
GT Biopharma Appoints Michael Handelman, CPA as Chief Financial Officer
November 17, 2020
GT Biopharma Announces Former Abraxis CEO, Bruce J. Wendel as Vice Chairman of GTBP Board of Directors
November 16, 2020
GT Biopharma Announces Publication of GTB-3550 TriKE Interim Results at the Prestigious 62nd American Society of Hematology (ASH) Annual Meeting
November 11, 2020
GT Biopharma Announces Publication of Trike(TM) Results Targeting Multiple B7H3 Positive Cancers
October 20, 2020
GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting
October 14, 2020
GT Biopharma Announces Advisory Board Appointments
October 12, 2020
GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologics
October 5, 2020